4-氰基噻吩-2-羧酸甲酯 | 67808-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4-氰基噻吩-2-羧酸甲酯
• 中文别名: 4-溴噻吩-2-羧酸甲酯
• 英文名称: methyl 4-nitrilethiophenecarboxylate
• 英文别名: methyl 4-cyanothiophene-2-carboxylate
• CAS: 67808-33-7
• 化学式: C₇H₅NO₂S
• mdl: MFCD05664843
• 分子量: 167.188
• InChiKey: TYOWYTNOORXRSB-UHFFFAOYSA-N

物化性质

• 沸点：
  286.6±25.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  78.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氰基噻吩-2-羧酸甲酯 在 sodium hydride 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 6.5h， 以52.3%的产率得到
  参考文献：
  名称：

  一类化合物及其在抗AML药物中的用途

  摘要：

  本发明涉及药物化学领域，公开了一类化合物及其在抗AML药物中的用途。具体涉及唑环取代噻吩类化合物、它们的制备方法、含有这些化合物的药用组合物以及它们的医疗用途，特别是作为FMS样酪氨酸激酶3的ITD突变型选择性抑制剂的用途。。

  公开号：

  CN108690006B
• 作为产物：
  描述：

  4-溴-2-噻吩甲醛 在 sodium chlorite 、 sodium dihydrogenphosphate 、 氯化亚砜 、 2-甲基-2-丁烯 作用下， 以 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 生成 4-氰基噻吩-2-羧酸甲酯
  参考文献：
  名称：

  Design and Synthesis of 4,5-Disubstituted-thiophene-2-amidines as Potent Urokinase Inhibitors

  摘要：

  A study of the S1 binding of lead 5-methylthiothiophene amidine 3, an inhibitor of urokinase-type plasminogen activator, was undertaken by the introduction of a variety of substituents at the thiophene 5-position. The 5-alkyl substituted and unsubstituted thiophenes were prepared using organolithium chemistry. Heteroatom substituents were introduced at the 5-position using a novel displacement reaction of 5-methylsulfonylthiophenes and the corresponding oxygen or sulfur anions. Small alkyl group substitution at the 5-position provided inhibitors equipotent with 3 but possessing improved solubility. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00787-9

文献信息

• Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06291514B1

  公开（公告）日：2001-09-18

  The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.

  本发明涉及以下式的化合物： 其中X为O、S或NR7，R1-R7、Y和Z如规范中所述，并且其水合物、溶剂合物或药用可接受的盐也被描述。还描述了制备上述式化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、胰蛋白酶、纤溶酶和尿激酶。其中某些化合物表现出对尿激酶的直接、选择性抑制，或者是用于形成具有这种活性的化合物的中间体。
• Compounds and compositons for treating C1s-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020037915A1

  公开（公告）日：2002-03-28

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 , X, Y and Z are defined in the specification.

  揭示了一种治疗急性或慢性疾病症状的方法，该疾病是由补体级联的经典途径介导的，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4、X、Y和Z。
• 2-唑环取代噻吩类PLK1抑制剂及其用途及其用 途
  申请人：中国药科大学

  公开号：CN103408540B

  公开（公告）日：2016-05-18

  本发明涉及药物化学领域，具体涉及2-唑环取代噻吩类PLK1抑制剂、它们的制备方法、含有这些化合物的药用组合物以及它们的医疗用途，特别是作为Polo样激酶1(Polo-like？kinase1，PLK1)抑制剂的用途。
• Methods of treating C1s-mediated diseases and conditions and compositions thereof
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06492403B1

  公开（公告）日：2002-12-10

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.

  本发明涉及一种治疗由补体级联经典途径介导的急性或慢性疾病症状的方法，包括向需要此类治疗的哺乳动物中投与化合物I的治疗有效量或其溶剂、水合物或药学上可接受的盐；其中R1、R2、R3、R4、X、Y和Z在规范中定义。
• Thiophene azo dyes and laundry care compositions containing the same
  申请人：The Procter & Gamble Company

  公开号：US10435651B2

  公开（公告）日：2019-10-08

  This application relates to thiophene azo dyes for use as hueing agents, laundry care compositions comprising such thiophene azo dyes, processes for making such thiophene azo dyes, and laundry care compositions and methods of using the same. The thiophene azo dyes contain a formally charged moiety and are generally comprised of at least two components: at least one chromophore component and at least one polymeric component. Suitable chromophore components generally fluoresce blue, red, violet, or purple color when exposed to ultraviolet light, or they may absorb light to reflect these same shades. These thiophene azo dyes are advantageous in providing a hueing effect, for example, a whitening effect to fabrics, while not building up over time and causing undesirable blue discoloration to the treated fabrics. The thiophene azo dyes are also generally stable to bleaching agents used in laundry care compositions.

  本申请涉及用作着色剂的噻吩偶氮染料、含有此类噻吩偶氮染料的衣物护理组合物、制造此类噻吩偶氮染料的工艺以及衣物护理组合物和使用方法。噻吩偶氮染料含有正式带电分子，通常由至少两种成分组成：至少一种发色团成分和至少一种聚合物成分。合适的发色团成分在紫外线照射下一般会发出蓝色、红色、紫色或紫罗兰色的荧光，也可以吸收光来反射这些相同的色调。这些噻吩偶氮染料在提供色调效果（例如，织物的增白效果）方面具有优势，同时不会随着时间的推移而积累，导致处理过的织物出现不希望看到的蓝色褪色。噻吩偶氮染料对洗衣护理组合物中使用的漂白剂通常也很稳定。